Hadassah

Israeli Biotech Company Forges Immunotherapy Collaboration with Hadassah

Wednesday, Nov 2 2016

Vaxil Biotherapeutics Israel has signed an immunotherapy collaboration agreement with the Hadassah Medical Organization, intended to enhance the Company's immunotherapy platform, including its lead product, Immucin™. 

"I am a strong believer in Vaxil's immunotherapy platform,” relates Prof. Michael Shapira, who is spearheading the collaboration and joining Vaxil’s Scientific Advisory Board. “I have spent years following Immucin's progress, and have been fortunate to witness the promising potential both in cancer patients and in the laboratory. Hadassah is excited to be embarking on this collaboration and partnering with Vaxil's scientific team." 

Through this collaboration, Hadassah cancer patients and healthy volunteers will provide tumor samples which will be analyzed in conjunction with Vaxil's immune therapies. They will also be used in Vaxil’s investigation of potential combination therapies. The company notes that Immucin has the potential to be a very strong immunotherapy, whether as a stand-alone treatment or possibly in combination with other products.

The Vaxil and Hadassah scientists will further examine the nature of immune response to its immunotherapy in hematological patients, specifically those that are in remission from multiple myeloma and leukemia. Investigations and analysis will take place primarily at Vaxil's laboratory, using the company's fluorescence-activated cell sorting machine and other facilities. Immucin has already completed a successful Phase-I/II clinical trial, under the direction of Prof. Shapira, and will now be positioned toward a larger Phase II trial. The previous trial demonstrated the safety of Immucin and established its potential to elicit a novel specific cellular response against a highly prominent cancer target entitled MUC1-SP--a target that is present on 90 percent of all human cancers, but has proven elusive in terms of optimal treatment protocol.

This Vaxil-Hadassah partnership will investigate Immucin’s mode of action and, in turn, create an optimal design for its next clinical trial, to be launched in 2017. Learn more about immunotherapy and Immucin at https://www.youtube.com/watch?v=XhEwj6Ue13s

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 22 2017

Hadassah Medical Organization Performs Israel’s First Spina Bifida Fetal Surgery To Lessen Crippling Spinal Damage

History was made at Hadassah Ein Kerem Hospital in Jerusalem on Thursday, February 9 when a team of Israeli surgeons successfully operated on a 5-month-old fetus using a new procedure that only three doctors in the world can perform, to alleviate some of the crippling effects of Spina Bifida.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Cardiologists Publicize Israel’s Dramatic Decrease in Cardiovascular Death

Prof. Emeritus Mervyn Gotsman and Prof. Israel Gotsman of Hadassah Hospital’s Heart Institute have coauthored an article which appeared in the European Heart Journal, highlighting the fact that “between 1998 and 2012, mortality from cardiovascular disease in Israel has fallen from 162 to 80 per 100,000 residents--a decrease of 50 percent.”

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Ambassadors of Health for Heart Smart Living: A Unique Hadassah Program

Knowing that the workplace is where people spend vast quantities of time, the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women launched a unique course to encourage heart healthy living—during the work day.

READ MORE ›
alt_text

Tuesday, Feb 21 2017

Hadassah Brings Health Empowerment to East Jerusalem

The increased incidence of diabetes in the Arab community, as well as the 60 percent higher rate of cardiovascular mortality among Arab women led the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women to develop a community-based program to cultivate leadership that embraces and advocates for healthy living which will reduce diabetes in this population.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More